[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.204.198.71. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
September 3, 2008

Clopidogrel Treatment and the MEND-CABG II Trial

JAMA. 2008;300(9):1021-1022. doi:10.1001/jama.300.9.1021-a

To the Editor: The MEND-CABG (MC-1 to Eliminate Necrosis and Damage in Coronary Artery Bypass Graft Surgery Trial) II investigators1 have shown that pyridoxal 5"-phosphate monohydrate (MC-1) did not reduce cardiovascular death or nonfatal myocardial infarction (MI) in intermediate- to high-risk patients undergoing coronary artery bypass graft (CABG) surgery. According to their data, there were no significant differences in concomitant medical therapies during hospitalization between the MC-1 and placebo groups (Table 4).

First Page Preview View Large
First page PDF preview
First page PDF preview
×